CAR T-cell therapy approved for B-cell lymphomas may save ‘thousands of lives’ in next few years – Healio
STAT |
CAR T-cell therapy approved for B-cell lymphomas may save 'thousands of lives' in next few years
Healio The agency on Oct. 18 approved axicabtagene ciloleucel (Yescarta; Kite, Gilead), a chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory large B-cell lymphoma who underwent two or more lines of systemic therapy. Revolutionary new cancer therapies come with big risks. Drug makers must be prepared Cellectis gets FDA go-ahead to restart fatal CAR–T trial |
